FDA OKs Rapid Test to Spot C. difficile Infection

Detects toxin gene sequences associated with the epidemic 027/NAP1/BI strain of the bacterium

FRIDAY, April 8 (HealthDay News) -- A test designed to rapidly detect the genetic fingerprint of Clostridium difficile bacterial infection has been approved by the U.S. Food and Drug Administration.

The Cepheid Xpert C. difficile/Epi assay detects toxin gene sequences associated with the epidemic 027/NAP1/BI strain of the bacterium in a person's stool. However, the test should not be used to determine or monitor treatment, the FDA said in a statement.

The best way to prevent infection is via thorough hand-washing with soap and warm water, the FDA said.

The new test is produced by Cepheid, based in Sunnyvale, Calif.

More information

To learn more about this infection, visit the U.S. Centers for Disease Control and Prevention.

Physician's Briefing